Aptose Biosciences Inc. Stockholders Equity

Quick Answer

Aptose Biosciences Inc. reported Stockholders Equity of -$27.17 million for fiscal year 2025.

Aptose Biosciences Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 -$27.17M -498.0%
2024 -$4.54M -56.6%
2023 -$2.90M -107.7%
2022 $37.74M -49.2%
2021 $74.24M -37.6%
2020 $118.92M +26.6%
2019 $93.93M +567.0%
2018 $14.08M +38.0%
2017 $10.20M +39.2%
2016 $7.33M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 -$19.45M -112.9% -35.3%
June 30, 2025 -$14.37M -560.4% -94.4%
March 31, 2025 -$7.39M -5496.4% -62.7%
December 31, 2024 -$4.54M -56.6% +50.3%
September 30, 2024 -$9.13M -217.5% -319.8%
June 30, 2024 -$2.18M -115.8% -1688.3%
March 31, 2024 $137.0K -99.5% +104.7%
December 31, 2023 -$2.90M -107.7% -137.3%
  • Aptose Biosciences Inc. showed a decrease of -498.0% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2016–2025 period, Aptose Biosciences Inc.’s stockholders equity has declined by 470.7% (from $7.33 million to -$27.17 million).
  • The most recent figure is from Aptose Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment